Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Zevra Therapeutics heads into its November 9 earnings report with a notable gap between what short sellers are betting and what analysts are saying.
Short interest is genuinely elevated at 10.4% of the free float, around 5.9 million shares, and has edged up roughly 0.8% over the past week after trending lower through September from a peak near 6.2 million shares in early that month. The borrow market, however, offers no particular squeeze pressure. Cost to borrow has climbed about 24% over the past month to reach 0.50%, still a low absolute level. Availability is loose at 640%, meaning roughly six shares are available to lend for every one already borrowed, well above the 52-week tightest reading of 201%. That picture argues the short position reflects genuine negative conviction rather than a supply-constrained technical setup. Options lean modestly defensive, with the put/call ratio at 1.34 against a 20-day average of 1.32, effectively unchanged and nowhere near the 52-week high of 1.73. Positioning, in sum, is cautious but not extreme.
The Street disagrees with the bears, though the analyst data is around two months old. All recent changes on record maintain Buy or Market Outperform ratings, with a mean price target of $25.00 against a current price of $11.08, implying substantial upside. After the August 5 results, Citizens raised its target to $28.00 and Guggenheim trimmed modestly to $23.00, both holding Buy. The bull case centres on the MIPLYFFA launch: $30.2 million in second-quarter net sales, 184 cumulative enrollment forms, high patient retention, and a large underpenetrated market where management estimates roughly 900 total prevalent US patients versus only 300 to 350 diagnosed. Zevra also carries more than $260 million in cash and no debt, which removes near-term liquidity concerns. Bears counter with commercial execution risk, reimbursement uncertainty, and the possibility that a competing approval slows the sales ramp. The EV/EBIT sits near 66x on a percentile basis, so valuation is stretched relative to peers, a point both camps acknowledge.
Ownership flows are a meaningful part of the story. FMR lifted its stake from 5.5% to 8.3% in its August 2026 13G/A filing, and Woodline Partners raised its position from 6.2% to 8.1% across filings in late 2025 and August 2026. Those two funds alone account for more than 16% of shares. BlackRock also added 652,000 shares as of September 30, bringing its holding to 8.6%. On the insider side, the net 90-day picture shows around $1.05 million in open-market selling, but the most significant item, 42,666 shares sold by the Chief Legal Officer in August, was executed under a pre-arranged 10b5-1 plan, which reduces its signalling value. There is no open-market buying on record in the recent window.
The last earnings print, delivered August 5, produced a 12.9% single-day gain and held most of that through the following week, rising a further 8.7% over five days. That reaction followed MIPLYFFA's first full commercial quarter and reset the narrative from launch-stage uncertainty to durable ramp. The stock has since given back about 11% over the past month to $11.08, recovering about 1% this week, leaving it well below both the analyst consensus target and the highs seen post-print.
With the next report 32 days away, the key question is whether the third-quarter enrollment and revenue trajectory supports the patient-funnel story management outlined in August, or whether the stock's retreat from post-earnings highs reflects early signs of fading momentum in the launch ramp.
See the live data behind this article on ORTEX.
Open ZVRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
